JP2016513128A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016513128A5 JP2016513128A5 JP2015559275A JP2015559275A JP2016513128A5 JP 2016513128 A5 JP2016513128 A5 JP 2016513128A5 JP 2015559275 A JP2015559275 A JP 2015559275A JP 2015559275 A JP2015559275 A JP 2015559275A JP 2016513128 A5 JP2016513128 A5 JP 2016513128A5
- Authority
- JP
- Japan
- Prior art keywords
- compound according
- group
- atoms
- ring
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 23
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 18
- 125000004429 atom Chemical group 0.000 claims 9
- 229910052757 nitrogen Inorganic materials 0.000 claims 9
- 150000003839 salts Chemical class 0.000 claims 8
- 125000001424 substituent group Chemical group 0.000 claims 8
- 239000000203 mixture Substances 0.000 claims 7
- 229910052760 oxygen Inorganic materials 0.000 claims 7
- 229910052717 sulfur Inorganic materials 0.000 claims 7
- 229910052799 carbon Inorganic materials 0.000 claims 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 5
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 4
- 239000002671 adjuvant Substances 0.000 claims 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 4
- 239000001301 oxygen Substances 0.000 claims 4
- 239000011593 sulfur Substances 0.000 claims 4
- 238000002255 vaccination Methods 0.000 claims 4
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 3
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 3
- 239000000460 chlorine Substances 0.000 claims 3
- 229910052801 chlorine Inorganic materials 0.000 claims 3
- 229910052731 fluorine Inorganic materials 0.000 claims 3
- 239000011737 fluorine Substances 0.000 claims 3
- 230000002163 immunogen Effects 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
- 125000006413 ring segment Chemical group 0.000 claims 3
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- 150000004678 hydrides Chemical class 0.000 claims 2
- 125000001183 hydrocarbyl group Chemical group 0.000 claims 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 210000004962 mammalian cell Anatomy 0.000 claims 2
- 125000002950 monocyclic group Chemical group 0.000 claims 2
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 claims 1
- 102100039360 Toll-like receptor 4 Human genes 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- IVRMZWNICZWHMI-UHFFFAOYSA-N azide group Chemical group [N-]=[N+]=[N-] IVRMZWNICZWHMI-UHFFFAOYSA-N 0.000 claims 1
- 125000002619 bicyclic group Chemical group 0.000 claims 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 230000003053 immunization Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361768712P | 2013-02-25 | 2013-02-25 | |
| US61/768,712 | 2013-02-25 | ||
| PCT/US2014/018380 WO2014131023A1 (en) | 2013-02-25 | 2014-02-25 | Neoseptins: small molecule adjuvants |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016513128A JP2016513128A (ja) | 2016-05-12 |
| JP2016513128A5 true JP2016513128A5 (enExample) | 2017-04-06 |
| JP6356160B2 JP6356160B2 (ja) | 2018-07-11 |
Family
ID=51391916
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015559275A Expired - Fee Related JP6356160B2 (ja) | 2013-02-25 | 2014-02-25 | ネオセプチン：低分子アジュバント |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US9649373B2 (enExample) |
| EP (1) | EP2958889B1 (enExample) |
| JP (1) | JP6356160B2 (enExample) |
| CN (1) | CN105339346B (enExample) |
| AU (1) | AU2014218598B2 (enExample) |
| CA (1) | CA2902342C (enExample) |
| WO (1) | WO2014131023A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014069063A1 (ja) | 2012-10-29 | 2014-05-08 | 京セラ株式会社 | 弾性表面波センサ |
| WO2016011195A1 (en) | 2014-07-17 | 2016-01-21 | Threshold Pharmaceuticals, Inc. | Th-302 solid forms and methods related thereto |
| SG11201707293VA (en) | 2015-03-10 | 2017-10-30 | Ascenta Pharmaceuticals Ltd | Dna alkylating agents |
| CN112142692A (zh) * | 2015-04-02 | 2020-12-29 | 深圳艾欣达伟医药科技有限公司 | 硝基苄基衍生物抗癌试剂 |
| EP3313385B8 (en) | 2015-06-24 | 2021-04-21 | ImmunoGenesis, Inc. | Aziridine containing dna alkylating agents |
| WO2017083823A1 (en) * | 2015-11-13 | 2017-05-18 | Brandeis University | Mtor inhibitors and methods of use thereof |
| CN109641878B (zh) * | 2016-06-29 | 2021-09-14 | 斯克里普斯研究学院 | Diprovocim：一类有效的tlr激动剂 |
| EP3710007A4 (en) | 2017-11-14 | 2021-12-15 | Children's Medical Center Corporation | USE OF IMIDAZOPYRIMIDINE TO MODULATE A HUMAN IMMUNE RESPONSE |
| JP7304855B2 (ja) | 2017-11-14 | 2023-07-07 | ザ チルドレンズ メディカル センター コーポレーション | 新規イミダゾピリミジン化合物およびそれらの使用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4045438A (en) | 1975-10-24 | 1977-08-30 | Yeda Research And Development Co. Ltd. | Cephalosporin antibiotics |
| US4031083A (en) | 1975-10-24 | 1977-06-21 | Yeda Research And Development Co., Ltd. | Cephalosporin antibiotics |
| US20050004144A1 (en) | 2003-04-14 | 2005-01-06 | Regents Of The University Of California | Combined use of IMPDH inhibitors with toll-like receptor agonists |
| EP1910387B1 (en) * | 2005-06-30 | 2016-11-16 | Eisai R&D Management Co., Ltd. | Compounds for preparing immunological adjuvant |
| EP1931352B1 (en) * | 2005-08-22 | 2016-04-13 | The Regents of The University of California | Tlr agonists |
| CA2656487A1 (en) * | 2006-07-07 | 2008-01-17 | The Board Of Trustees Of The Leland Stanford Junior University | Selective caspase inhibitors |
| JP5425642B2 (ja) * | 2007-02-07 | 2014-02-26 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 合成ｔｌｒアゴニストの結合体およびそのための使用 |
| PT2268618E (pt) * | 2008-03-03 | 2015-10-12 | Novartis Ag | Compostos e composições moduladores da actividade tlr |
| WO2010037402A1 (en) * | 2008-10-02 | 2010-04-08 | Dako Denmark A/S | Molecular vaccines for infectious disease |
| BRPI1008063A2 (pt) * | 2009-01-30 | 2015-08-25 | Idera Pharmaceuticals Inc | Agonistas sinteticas de tlr9 |
-
2014
- 2014-02-25 US US14/770,002 patent/US9649373B2/en not_active Expired - Fee Related
- 2014-02-25 WO PCT/US2014/018380 patent/WO2014131023A1/en not_active Ceased
- 2014-02-25 JP JP2015559275A patent/JP6356160B2/ja not_active Expired - Fee Related
- 2014-02-25 EP EP14754704.6A patent/EP2958889B1/en not_active Not-in-force
- 2014-02-25 CA CA2902342A patent/CA2902342C/en not_active Expired - Fee Related
- 2014-02-25 AU AU2014218598A patent/AU2014218598B2/en not_active Ceased
- 2014-02-25 CN CN201480023040.6A patent/CN105339346B/zh not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016513128A5 (enExample) | ||
| CY1120342T1 (el) | Ανταγωνιστης πολυκυκλικου lpa1 και χρησεις εξ' αυτου | |
| MX384752B (es) | ANTAGONISTAS SOLUBLES DE RECEPTOR DE C5a (C5aR). | |
| RU2018138828A (ru) | Уменьшение массы опухоли путем введения ccr1 антагонистов в комбинации с pd-1 ингибиторами или pd-l1 ингибиторами | |
| PE20181269A1 (es) | Agonistas del receptor de apelina y metodos de uso | |
| JP2013510124A5 (enExample) | ||
| PE20080552A1 (es) | Derivados de alcoholes 1-fenil-2-piridinil alquilenicos como inhibidores de fosfodiesterasa | |
| EA201590873A1 (ru) | Соединения, обладающие активностью антагонистов мускариновых рецепторов и агонистов бета2 адренергических рецепторов | |
| RU2013142448A (ru) | Новые сульфонаминохинолиновые антагонисты гепсидина | |
| CL2016000816A1 (es) | Forma de dosificación que comprende al compuesto (s)-3-(4-((4-morfolinometil)bencil)oxi)-1-oxoisoindolin-2-il)piperidin-2,6-diona, una cantidad de 90 hasta 99,9 por ciento en peso del peso total de una mezcla de almidón y lactosa como portador o excipiente, y acido esteárico como lubricante; su uso en el tratamiento de cáncer y enfermedades autoinmunes, entre otras. | |
| PE20121474A1 (es) | Nuevos compuestos de espiropiperidina | |
| JP2013510123A5 (enExample) | ||
| RU2018120318A (ru) | ИМИДАЗО[4,5-c]ХИНОЛИН-2-ОНОВЫЕ СОЕДИНЕНИЯ И ИХ ПРИМЕНЕНИЕ В ЛЕЧЕНИИ РАКА | |
| JP2015516427A5 (enExample) | ||
| EA201391662A1 (ru) | Соединения с активностью антагонистов мускариновых рецепторов и агонистов адренергического рецептора бета2 | |
| AR080467A1 (es) | Derivados tetrazolicos moduladores selectivos de receptores cb2, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del dolor y otras enfermedades | |
| PE20190806A1 (es) | Agonistas heterociclicos del receptor de apelina (apj) y usos de los mismos | |
| RU2015118581A (ru) | Лиофилизированные препараты мелфалана флуфенамида | |
| JP2013523814A5 (enExample) | ||
| AR054485A1 (es) | ARIL-ALQUILAMINAS Y HETEROARIL-ALQUILAMINAS COMO INHIBIDORES DE PROTEINA QUINASA A Y B, UN PROCESO PARA SU PREPARACION, COMPOSICIONES FARMACEUTICAS QUE LAS CONTIENEN Y SU USO EN LA FABRICACIoN DE MEDICAMENTOS PARA EL TRATAMIENTO O PROFILAXIS DE ENFERMEDADES ORIGINADAS EN EL CRECIMIENTO ANORMAL DE LA | |
| CR20170371A (es) | Compuestos de benzoxaboral 4-sustituidos y uso de los mismos | |
| CL2008003383A1 (es) | Compuestos derivados de (espiro piperidin)-benzamida, inhibidores del transportador equilibrativo de nucleosidos ent1; composicion farmaceutica que comprende uno de los compuestos; proceso para preparar la composicion; y proceso para preparar los compuestos, utiles para tratamientos del dolor agudo y cronico. | |
| AR057770A1 (es) | Inhibidores de la p38-map-quinasa y composicion farmaceutica | |
| AR074353A1 (es) | Acidos naftalen-2-il-aceticos sustituidos, composiciones farmaceuticas que los contienen, y uso de los mismos en el tratamiento de enfermedades alergicas,tales como rinitis, asma y dermatititis atopica. | |
| EA201691252A1 (ru) | Соединения индазола в качестве агонистов 5-ht-рецептора |